HIV: key endpoint results by drug
The key endpoints of HIV trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the HIV page.
HIV-1 RNA below 50 copies/mL (week 48) (maintenance)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Bictegravir | 92.4% | 93% (ABC/DTG/3TC) | — | wk 48 · n 314 | NCT02607930 Phase 3, primary |
| Cabotegravir/rilpivirine (Cabenuva) | 94% | 91% (CAB 30 mg+ABC/3TC) | — | IM-Q4W · wk 32 · n 115 | NCT02120352 Phase 2, primary |
| Dolutegravir | 88% | 85% (RTG) | — | 50 mg Once a Day · wk 48 · n 411 | NCT01227824 Phase 3, primary |
| Doravirine | 83.8% | 79.9% (Daurunavir + Ritonavir) | — | 100 mg · wk 48 · n 383 | NCT02275780 Phase 3, primary |
| Elvitegravir | 87.6% | 84.1% (Atripla) | — | wk 48 · n 348 | NCT01095796 Phase 3, primary |
| Emtricitabine/tenofovir disoproxil fumarate | 83.8% | 79.9% (Daurunavir + Ritonavir) | — | 100 mg · wk 48 · n 383 | NCT02275780 Phase 3, primary |
| Etravirine | 56%a | 39% | +17 | wk 24 | NCT00254046 Phase 3, primary |
| Fostemsavir | 72% | 75% (ATV/r) | — | 1200 mg QD · wk 24 · n 50 | NCT01384734 Phase 2, primary |
| Lenacapavir (Sunlenca) | 90.4% | 92% (B/F/TAF) | — | wk 54 · n 52 | NCT04143594 Phase 2, primary |
| Maraviroc | 41.8% | 16.1% | +25.7 | QD · wk 48 · n 232 | NCT00098306 Phase 2/3, secondary |
| Rilpivirine | 94% | 94% (CAR) | — | DTG 50 mg + RPV 25 mg · wk 48 · n 261 | NCT02422797 Phase 3, primary |
| Tenofovir alafenamide/emtricitabine | 94.3% | 93% (FTC/TDF) | — | wk 48 · n 333 | NCT02121795 Phase 3, primary |
Drugs checked with no result here: 9 not posted, 9 not reported, 11 trial running.
HIV-1 RNA 50 copies/mL or more (week 48) (maintenance)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Bictegravir | 0.4% | 1.1% (DTG + F/TAF) | — | wk 48 · n 284 | NCT03110380 Phase 3, primary |
| Cabotegravir/rilpivirine (Cabenuva) | 0% | 0% (DTG + RPV) | — | Q2M · wk 48 · n 90 | NCT03639311 Phase 2, primary |
| Doravirine | 0% | 1.5% (Baseline Antiretroviral Therapy (ART)) | — | wk 48 · n 336 | NCT04223778 Phase 3, primary |
| Rilpivirine | 0.6% | 0% (FTC/RPV/TDF) | — | wk 48 · n 316 | NCT02345252 Phase 3, secondary |
| Tenofovir alafenamide/emtricitabine | 0.4% | 1.1% (DTG + F/TAF) | — | wk 48 · n 284 | NCT03110380 Phase 3, primary |
Drugs checked with no result here: 12 not posted, 11 not reported, 13 trial running.
CD4 count, change (week 48) (maintenance)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Bictegravir | 180 | 201 (DTG + F/TAF) | — | wk 48 · n 290 | NCT02607956 Phase 3, secondary |
| Cabotegravir/rilpivirine (Cabenuva) | 263.7 | 346.1 (CAB 30 mg+ABC/3TC) | — | IM-Q4W · wk 32 · n 108 | NCT02120352 Phase 2, secondary |
| Darunavir | 5 | 41 (SBR) | — | wk 48 · n 85 | NCT01968551 Phase 3, secondary |
| Dolutegravir | 115 | 156 | −41 | 50 mg BID · wk 48 · n 14 | NCT01568892 Phase 3, secondary |
| Doravirine | 192.7 | 185.6 (Daurunavir + Ritonavir) | — | 100 mg · wk 48 · n 363 | NCT02275780 Phase 3, secondary |
| Elvitegravir | 239 | 206 (Atripla) | — | wk 48 · n 348 | NCT01095796 Phase 3, secondary |
| Emtricitabine/tenofovir disoproxil fumarate | 192.7 | 185.6 (Daurunavir + Ritonavir) | — | 100 mg · wk 48 · n 363 | NCT02275780 Phase 3, secondary |
| Fostemsavir | 155.4 | 178.7 (ATV/r) | — | 1200 mg QD · wk 48 · n 50 | NCT01384734 Phase 2, secondary |
| Lenacapavir (Sunlenca) | 204 | 193 (B/F/TAF) | — | wk 54 · n 49 | NCT04143594 Phase 2, secondary |
| Maraviroc | 112.5 | 54.0 | +58.6 | QD · wk 48 · n 227 | NCT00098306 Phase 2/3, secondary |
| Raltegravir | 98.4 | 39.8 | +58.6 | 400 mg b.i.d. · wk 48 · n 217 | NCT00293254 Phase 3, secondary |
| Rilpivirine | 28 | 18.4 (CAR) | — | DTG 50 mg + RPV 25 mg · wk 48 · n 261 | NCT02422797 Phase 3, secondary |
| Tenofovir alafenamide/emtricitabine | 60 | 42 (Baseline Treatment Regimen (SBR)) | — | wk 96 · n 959 | NCT01815736 Phase 3, secondary |
| Tipranavir | 43 | 16 (Comparator Protease Inhibitor) | — | wk 48 · n 430 | NCT00144170 Phase 3, secondary |
Drugs checked with no result here: 8 not posted, 8 not reported, 11 trial running.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 41 approved or late-stage drugs with a featured trial in HIV were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.